US FDA Generic Drug Applications Will Cost Less In FY 2020

 
• By Sue Sutter

Increases in the number of expected ANDA submissions, facilities and entities holding approved applications means lower user fees in most GDUFA II categories starting 1 October; program fee will see the largest percentage drop, amounting to savings of $200,000 for large companies.  

People, Hand paying toll way on the road. colorful, background - Image
Come October, generic drug sponsors will pay the US FDA less for each application. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics